Shandong Wit Dyne Health(000915.SZ) subsidiary obtains a drug registration certificate.

15:54 07/01/2026

Huatai Dain (000915.SZ) announced that its subsidiary, Shandong Dain Marine Bio-pharmaceutical Co., Ltd. (referred to as Dain Pharmaceutical), has received the "Drug Registration Certificate" issued by the National Medical Products Administration. The drug's name is: Methylphenidate Hydrochloride Extended-Release Tablets. This product is used for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years as a monotherapy or as an adjunct to central stimulant therapy.

Shandong Wit Dyne Health (000915.SZ) announced that its subsidiary Shandong Dain Ocean Biopharmaceutical Co., Ltd. (referred to as Dain Pharmaceuticals) has received a "Drug Registration Certificate" from the National Medical Products Administration. The drug's name is: Methylphenidate Hydrochloride Sustained-Release Tablets. This product is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17, either alone or as an adjunct to central stimulants.

Zhubo Design (300564.SZ) shareholders Yang weizhong and executive Ma Zhenyan plan to reduce their holdings by no more than 1.91%.

Zhubo Design (300564.SZ) Several shareholders plan to reduce their holdings by no more than 3%.

China Fortune Land Development (600340.SH): It is expected that the net profit attributable to the shareholders of the listed company in 2025 will be negative.

Zhubo Design (300564.SZ) shareholders Yang weizhong and executive Ma Zhenyan plan to reduce their holdings by no more than 1.91%.

Zhubo Design (300564.SZ) Several shareholders plan to reduce their holdings by no more than 3%.

China Fortune Land Development (600340.SH): It is expected that the net profit attributable to the shareholders of the listed company in 2025 will be negative.